179 related articles for article (PubMed ID: 9334595)
1. Atropine role in the pharmacological erection test: study of 228 patients.
Sogari PR; Telöken C; Souto CA
J Urol; 1997 Nov; 158(5):1760-3. PubMed ID: 9334595
[TBL] [Abstract][Full Text] [Related]
2. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
Allen RP; Engel RM; Smolev JK; Brendler CB
J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
[TBL] [Abstract][Full Text] [Related]
3. Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction.
Waldhauser M; Schramek P
J Urol; 1988 Sep; 140(3):525-7. PubMed ID: 3045341
[TBL] [Abstract][Full Text] [Related]
4. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
[TBL] [Abstract][Full Text] [Related]
5. [Evaluation of 452 patients with erectile dysfunction treated by combinations of vasoactive agents by penile injection].
Segenreich E; Israilov S; Shmueli J; Simon D; Baniel J; Livne P
Harefuah; 1998 May; 134(9):673-8, 750. PubMed ID: 10909609
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
Lee LM; Stevenson RW; Szasz G
J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
[TBL] [Abstract][Full Text] [Related]
7. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients.
Stief CG; Wetterauer U; Schaebsdau FH; Jonas U
J Urol; 1991 Oct; 146(4):1010-4. PubMed ID: 1895414
[TBL] [Abstract][Full Text] [Related]
8. Experience with intracavernosal tri-mixture for the management of neurogenic erectile dysfunction.
Chao R; Clowers DE
Arch Phys Med Rehabil; 1994 Mar; 75(3):276-8. PubMed ID: 8129578
[TBL] [Abstract][Full Text] [Related]
9. Four-drug intracavernous therapy for impotence due to corporeal veno-occlusive dysfunction.
Montorsi F; Guazzoni G; Bergamaschi F; Ferini-Strambi L; Barbieri L; Rigatti P
J Urol; 1993 May; 149(5 Pt 2):1291-5. PubMed ID: 7683061
[TBL] [Abstract][Full Text] [Related]
10. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
[TBL] [Abstract][Full Text] [Related]
12. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
Floth A; Schramek P
J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
[TBL] [Abstract][Full Text] [Related]
13. A prospective double-blind trial of intracorporeal papaverine versus prostaglandin E1 in the treatment of impotence.
Sarosdy MF; Hudnall CH; Erickson DR; Hardin TC; Novicki DE
J Urol; 1989 Mar; 141(3):551-3. PubMed ID: 2645420
[TBL] [Abstract][Full Text] [Related]
14. Progressive treatment of erectile dysfunction with intracorporeal injections of different combinations of vasoactive agents.
Shmueli J; Israilov S; Segenreich E; Baniel J; Livne P
Int J Impot Res; 1999 Feb; 11(1):15-9. PubMed ID: 10098948
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, cross-over study comparing prostaglandin E1 and papaverine in patients with vasculogenic impotence.
Kattan S; Collins JP; Mohr D
Urology; 1991 Jun; 37(6):516-8. PubMed ID: 2038782
[TBL] [Abstract][Full Text] [Related]
16. Nocturnal penile tumescence predicting response to intracorporeal pharmacological erection testing.
Allen RP; Brendler CB
J Urol; 1988 Sep; 140(3):518-22. PubMed ID: 3411665
[TBL] [Abstract][Full Text] [Related]
17. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
[TBL] [Abstract][Full Text] [Related]
18. An improved vasoactive drug combination for a pharmacological erection program.
Bennett AH; Carpenter AJ; Barada JH
J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
[TBL] [Abstract][Full Text] [Related]
19. Prostaglandin E1 therapy for impotence, comparison with papaverine.
Earle CM; Keogh EJ; Wisniewski ZS; Tulloch AG; Lord DJ; Watters GR; Glatthaar C
J Urol; 1990 Jan; 143(1):57-9. PubMed ID: 2294263
[TBL] [Abstract][Full Text] [Related]
20. Determinants of satisfactory rigidity after intracavernosal injection with prostaglandin E1 in men with erectile failure.
Purvis K; Brekke I; Christiansen E
Int J Impot Res; 1996 Mar; 8(1):9-16. PubMed ID: 8735188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
